“In a recent publication, Schwartz et al (2013) present a cost-benefit analysis of “interim treatment” (IM). They confirmed their earlier outcomes-oriented findings (Schwartz et al., 2012), including the similarity in retention. The retention rate of IM patients is especially remarkable since unlike standard methadone patients they “were not eligible for the motivational incentive of obtaining a take-home dose … after the first 90 days of treatment.
Surely this study should lead to an immediate radical change in governmental regulations and in self-imposed program policies as they relate to waiting lists. More generally, however, there should be open-minded reconsideration of imposing on both programs and patients a host of psychosocial services that in many instances neither can afford, and that both might believe are unnecessary.”
Journal of Addiction Medicine: July/August 2014 – Volume 8 – Issue 4 – p 295-296